OTHER INFORMATION
−Removed: the fiscal quarter ended June 30, 2024, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities
+Added: the fiscal quarter ended September 30, 2024, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities
Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as
such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended).
−Removed: Elite Pharmaceuticals, Inc.
−Removed: Restated 2014 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 to the form 10-K filed with the SEC on July 1, 2024.
−Removed: Asset Purchase Agreement, dated June 17, 2024 by and between the Company and Nostrum Laboratories Inc., incorporated by reference to Exhibit 10.59 to the Form 10-K filed with the SEC on July 1, 2024.
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
−Removed: Instance Document
−Removed: Taxonomy Schema Document
−Removed: Taxonomy Extension Calculation Linkbase Document
−Removed: Taxonomy Extension Definition Linkbase Document
−Removed: Taxonomy Extension Label Linkbase Document
−Removed: Taxonomy Extension Presentation Linkbase Document
+Added: XBRL Instance Document
+Added: XBRL Taxonomy Schema Document
+Added: XBRL Taxonomy Extension Calculation Linkbase Document
+Added: XBRL Taxonomy Extension Definition Linkbase Document
+Added: XBRL Taxonomy Extension Label Linkbase Document
+Added: XBRL Taxonomy Extension Presentation Linkbase Document
Page Interactive Data File (embedded within the Inline XBRL document)
+Added: Filed herewith.
+Added: Furnished herewith.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.